Making Progress for Improving Patient Lives: Clinical Advances in the First-Line Treatment of Advanced Squamous Non—Small Cell Lung Cancer
This activity includes:
- CME/CE-Certified Live Grand Rounds and Webinars
- Downloadable Slide Deck
(a non-certified educational resource; scheduled release date of December 2016)
The goal of this activity is to close educational gaps by providing clinicians with the latest evidence-based data about current and emerging agents for the first-line treatment of advanced or metastatic squamous non-small cell lung cancer (NSCLC).
In 2016, the American Cancer Society estimated that there were 224,390 new cases of lung and bronchus cancer in the United States. Lung cancer accounted for more deaths than any other cancer in both men and women, with an estimated 158,080 deaths in the United States in 2016 (American Cancer Society, 2016). Squamous histology accounts for 25% to 30% of NSCLC (Erickson and Wistuba, 2010; Thatcher et al, 2014) with the majority of patients presenting with locally advanced or metastatic disease. Five-year survival rates for this patient population are less than 5%. Results from recent trials and recent FDA approvals provide important advances in the search for new treatment options for patients with metastatic squamous NSCLC, where limited progress has been made over the past two decades (Thatcher et al, 2014).
Clinicians need to remain apprised of emerging data offering additional treatment options for NSCLC, specifically for the first-line treatment of advanced or metastatic squamous NSCLC where few advances have been made over the past two decades and few options exist. This activity will address educational gaps related to the first-line treatment of advanced or metastatic squamous NSCLC and, as a result, help participants to make more informed decisions for their patients.
- Activity Overview
- Understanding Squamous NSCLC Histology
- Current and Emerging Agents for First-Line Treatment of Advanced or Metastatic Squamous NSCLC
- Practical Application Case Studies
- Activity Conclusion and Question & Answer Session
This initiative is intended for medical oncologists, thoracic oncologists, pulmonologists, oncology nurses, advanced practitioners, and other healthcare professionals who treat or manage squamous NSCLCs.
- Identify the common features of squamous lung cancer histologic subtype
- Describe current treatment options and guideline recommendations for the first-line treatment of advanced or metastatic squamous non–small cell lung cancer (NSCLC)
- Assess the latest data on the efficacy and safety of recently approved and emerging therapies in the first-line treatment of advanced or metastatic squamous NSCLC
- Evaluate the risk-benefit profile of recently approved therapies to inform treatment selection
- Develop strategies to manage adverse events associated with treatments for advanced or metastatic NSCLC
David R. Gandara, MD
Walter J. Curran, Jr. MD, FACR
Fred R. Hirsch, MD, PhD
Paul K. Paik, MD
Jonathan Riess, MD
Thomas E. Stinchcombe, MD
Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.
This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit
To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Completion of the post-test with a score of 75% or better and the post-activity evaluation is requested. Your statement of credit will be emailed to you within 3 weeks.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|David R. Gandara, MD |
David R. Gandara, MD reported a financial interest/relationship or affiliation in the form of: Consultant: Ariad, Astra Zeneca, Boehringer-Ingleheim, Celgene, Clovis, Genentech, Guardant Health, Lilly, Merck, Mirati, Novartis, Pfizer Grant/Research Support (paid to institution): Astra Zeneca, Bristol-Myers Squibb, Clovis, Genentech, Johnson & Johnson Lilly, Merck, Novartis
Walter J. Curran, Jr. MD, FACR
|Walter J. Curran, Jr., MD reported a financial interest/relationship or affiliation in the form of: Received income in any amount from, Bristol-Myers Squibb Company, AstraZeneca Pharmaceuticals LP; Ownership interest, Nanthealth.|
Fred R. Hirsch, MD, PhD
Fred R. Hirsch, MD, PhD reported a financial interest/relationship or affiliation in the form of: Consultant/Advisory boards: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Co; Eli Lilly and Co; Genentech, Inc; Merck & Co., Inc; Ventana; Research grant through University of Colorado Lab: Amgen, Inc; Bayer Pharmaceuticals Corp; Eli Lilly and Co; Genentech, Inc.
|Paul K. Paik, MD||Paul K. Paik, MD reported a financial interest/relationship or affiliation in the form of: Consultant: Lilly, Celgene, EMD Serono Grant/Research Support: Celgene, Bristol-Myers Squibb, GlaxoSmithKline, EMD Serono Honoraria: Lilly, Celgene, EMD Serono|
|Jonathan Riess, MD||Jonathan Riess, MD reported a financial interest/relationship or affiliation in the form of: Consultant: Celgene, Ariad, Clovis Oncology, MedTronic Grant/Research Support (paid to institution): Merck, Novartis, Millennium|
|Thomas E. Stinchcombe, MD||Thomas E. Stinchcombe, MD reported a financial interest/relationship or affiliation in the form of: |
Consultant: Ariad, Boehringer-Ingleheim, Helsinn, Bristol-Myers Squibb, AbbVIE Grant/Research Support (paid to institution): Genentech, AbbVIE, EMD Serono
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Planner or Manager||Reported Financial Relationship|
|Ashley Marostica, RN, MSN||Nothing to disclose|
|Amanda Glazar, PhD||Nothing to disclose|
|Andrea Funk||Nothing to disclose|
|Laura Gilsdorf||Nothing to disclose|
|Linda Gracie-King, MS||Nothing to disclose|
|Ronald Viggiani, MD||Nothing to disclose|
|Jocelyn Timko, BS||Nothing to disclose|
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and AXIS Medical Education do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Physician Payments Sunshine Act
As of August 1, 2013, pharmaceutical companies are required by the new Centers for Medicare & Medicaid Services Open Payments program (a.k.a. the Physician Payments Sunshine Act) to account for certain transfers of value provided to physicians, including certain meals served to attendees of CME activities, unless specific factors are met. This CME-certified activity is currently supported by educational grants from commercial interest entities. Therefore, if your institution will not be able to ensure 50 or more physicians in attendance at the activity, we are unable to provide catering. Please feel free to contact us should you have any questions. Thank you for your understanding.
Americans with Disabilities Act
In compliance with the Americans with Disabilities Act, we will make every reasonable effort to accommodate your request. For any special requests, please contact AXIS at email@example.com before the meeting dates.
Supported by educational grants from Genentech and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
There is no fee for this educational activity.
This activity is provided by
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Attendance